Outlook Therapeutics Wins USFDA Nod for Lytenava, Marks First U.S. Commercial Launch

Published On 2026-07-27 17:11 GMT | Update On 2026-07-27 17:11 GMT

Bengaluru: Outlook Therapeutics said on Friday the U.S. Food and Drug Administration has approved its drug for a type of eye disease ‌that ⁠can ⁠cause severe vision loss.

The New Jersey-based company was seeking approval for Lytenava to treat wet age-related macular degeneration (AMD), a chronic eye disease that can cause blurred vision and blind spots and is a ⁠leading cause ‌of blindness among older adults.

The drug is an ophthalmic ⁠formulation of bevacizumab, an FDA-approved antibody therapy that works by inhibiting the growth of abnormal blood vessels that can damage the retina in patients with wet AMD.

Also Read: FDA Approves First OTC Acetaminophen-Naproxen Combination Tablet

The approval marks Outlook's first commercial entry into ‌the U.S. market and validates a years-long regulatory effort that included multiple FDA rejection letters ⁠and a successful appeal to the agency's Office of New Drugs, which ultimately agreed with the company on the drug's efficacy.

The company's shares were halted during afternoon trading.

Also Read: FDA Approves First Bevacizumab Formulation Specifically for Wet AMD

Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

sheeba farhat

Sheeba Farhat Joined Medical Dialogues in 2018 to report on the latest Education news. A Graduate of the University of Delhi, she specializes in covering stories related to Medical Education updates. For inquiries or further information, you can reach her at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Outlook Therapeutics Wins USFDA Nod for Lytenava, Marks First U.S. Commercial Launch

Similar News

Pharma Executive Loses Rs 26 Lakh in Fake Government Job Promise

Pharmacist Exposes Alleged Rs 1 Lakh Bribe Demand, Civil Surgeon Arrested

Indian Pharma Must Reduce US Dependence Amid Proposed Generic Drug Tariffs: Experts

USFDA Advisory Panel Recommends Expanded Access to Six Unapproved Compounded Peptides

CDSCO Cancels Registration of Seven Ethics Committees for Major Compliance Failures

Panacea Biotec Arm Slapped with GST Show Cause Notice Over Rs 4.06 Crore Alleged ITC Claim

Akums Arm to Acquire Oriflame India's Manufacturing Facilities for Rs 56 Crore